The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
M-1/M-2 Macrophages and the Th1/Th2 Paradigm
Mills, C. D., Kincaid, K., Alt, J. M., Heilman, M. J., & Hill, A. M. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6166 · Cited by 3,287
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Huang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Diaz-Montero, C. M., Salem, M. L., Nishimura, M. I., Garrett-Mayer, E., Cole, D. J., & Montero, A. J. (2009) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-008-0523-4 · Cited by 1,215
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Nagaraj, S., Gupta, K., Pisarev, V., Kinarsky, L., Sherman, S., Kang, L., Herber, D. L., Schneck, J., & Gabrilovich, D. I. (2007) · Nature Medicine · doi:10.1038/nm1609 · Cited by 1,174
Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R., & Albelda, S. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0883 · Cited by 1,054
Zea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 851
Kusmartsev, S., Nefedova, Y., Yoder, D., & Gabrilovich, D. I. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.2.989 · Cited by 850
Sinha, P., Clements, V. K., Bunt, S. K., Albelda, S. M., & Ostrand-Rosenberg, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.2.977 · Cited by 847
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells
Gallina, G., Dolcetti, L., Serafini, P., Santo, C. D., Marigo, I., Colombo, M. P., Basso, G., Brombacher, F., Borrello, I., Zanovello, P., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28828 · Cited by 792
SERAFINI, P., BORRELLO, I., & BRONTE, V (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.07.005 · Cited by 762
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand-Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 725
Myeloid Suppressor Lines Inhibit T Cell Responses by an NO-Dependent Mechanism
Mazzoni, A., Bronte, V., Visintin, A., Spitzer, J. H., Apolloni, E., Serafini, P., Zanovello, P., & Segal, D. M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.2.689 · Cited by 690
Bunt, S. K., Yang, L., Sinha, P., Clements, V. K., Leips, J., & Ostrand-Rosenberg, S. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2354 · Cited by 633
Mechanism of Immune Dysfunction in Cancer Mediated by Immature Gr-1+ Myeloid Cells
Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M., & Kast, W. M. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5398 · Cited by 538
Arginase, Prostaglandins, and Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma
Ochoa, A. C., Zea, A. H., Hernandez, C., & Rodriguez, P. C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2197 · Cited by 489
Sinha, P., Clements, V. K., & Ostrand-Rosenberg, S. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.636 · Cited by 466
Nowak, A. K., Lake, R. A., Marzo, A. L., Scott, B., Heath, W. R., Collins, E. J., Frelinger, J. A., & Robinson, B. W. S. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.10.4905 · Cited by 463
Kusmartsev, S. A., Cheng, F., Yu, B., Nefedova, Y., Sotomayor, E. M., Lush, R. M., & Gabrilovich, D. I. (2003) · PubMed · Cited by 460
STAT1 Signaling Regulates Tumor-Associated Macrophage-Mediated T Cell Deletion
Kusmartsev, S., & Gabrilovich, D. I. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.8.4880 · Cited by 445
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2003) · PubMed · Cited by 421
Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)
Bergman, A. M., Pinedo, H. M., & Peters, G. J. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00002-x · Cited by 360
Role Of Immature Myeloid Cells in Mechanisms of Immune Evasion In Cancer
Kusmartsev, S., & Gabrilovich, D. I. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0048-z · Cited by 346
Talmadge, J. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0182 · Cited by 285
Nowak, A. K., Robinson, B. W. S., & Lake, R. (2002) · PubMed · Cited by 238
Ko, H.-J., Kim, Y.-J., Kim, Y.-S., Chang, W.-S., Ko, S.-Y., Chang, S.-Y., Sakaguchi, S., & Kang, C.-Y. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4639 · Cited by 203
Bouffard, D. Y., Laliberté, J., & Momparler, R. L. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90444-2 · Cited by 192
Gemcitabine: A cytidine analogue active against solid tumors
Hui, Y. F., & Reitz, J. (1997) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/54.2.162 · Cited by 177
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
Plate, J. M. D., Plate, A. E., Shott, S., Bograd, S., & Harris, J. E. (2005) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-004-0638-1 · Cited by 176
Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection.
Seung, L. P., Rowley, D. A., Dubey, P., & Schreiber, H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.14.6254 · Cited by 170
Wang, L., Munch-Petersen, B., Herrström Sjöberg, A., Hellman, U., Bergman, T., Jörnvall, H., & Eriksson, S. (1999) · FEBS Letters · doi:10.1016/s0014-5793(98)01711-6 · Cited by 167
Sebastiani, V., Ricci, F., Rubio-Viquiera, B., Kulesza, P., Yeo, C. J., Hidalgo, M., Klein, A., Laheru, D., & Iacobuzio-Donahue, C. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2655 · Cited by 160
Immortalized Myeloid Suppressor Cells Trigger Apoptosis in Antigen-Activated T Lymphocytes
Apolloni, E., Bronte, V., Mazzoni, A., Serafini, P., Cabrelle, A., Segal, D. M., Young, H. A., & Zanovello, P. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.12.6723 · Cited by 157
Shipley, L. A., Brown, T. J., Cornpropst, J. D., Hamilton, M. L., Daniels, W. D., & Culp, H. W. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08805-1 · Cited by 148
Bernhard, H., Neudorfer, J., Gebhard, K., Conrad, H., Hermann, C., Nährig, J., Fend, F., Weber, W., Busch, D. H., & Peschel, C. (2007) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-007-0355-7 · Cited by 146
Beatty, G. L., & Paterson, Y. Y. W. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5502 · Cited by 119
Kmieciak, M., Knutson, K. L., Dumur, C. I., & Manjili, M. H. (2007) · European Journal of Immunology · doi:10.1002/eji.200636639 · Cited by 108
Self-citationMyeloid suppressor cells regulate the adaptive immune response to cancer
Frey, A. B. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29906 · Cited by 94
Merriman, R. L., Hertel, L. W., Schultz, R. M., Houghton, P. J., Houghton, J. A., Rutherford, P., Tanzer, L. R., Boder, G. B., & Grindey, G. B. (1996) · Investigational New Drugs · doi:10.1007/bf00194526 · Cited by 88
Broomfield, S., Currie, A. J., der Most, R. G. V., Brown, M. D., van Bruggen, I., Robinson, B. W. S., & Lake, R. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0328 · Cited by 87
Suzuki, E., Sun, J., Kapoor, V., Jassar, A. S., & Albelda, S. Μ. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.6.4090 · Cited by 77
Habibi, M., Kmieciak, M., Graham, L., Morales, J. K., Bear, H. D., & Manjili, M. H. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0024-3 · Cited by 68
Self-citationMorales, J. K., Kmieciak, M., Graham, L., Feldmesser, M., Bear, H. D., & Manjili, M. H. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0609-z · Cited by 66
Self-citationCyclophosphamide and abrogation of tumor-induced suppressor T cell activity
Hoover, S. K., Barrett, S. K., Turk, T. M. T., Lee, T., & Bear, H. D. (1990) · Cancer Immunology Immunotherapy · doi:10.1007/bf01742376 · Cited by 59
Self-citationSmith, J. A. (2003) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.09.037 · Cited by 25
Cited by
Myeloid-Derived Suppressor Cells
Gabrilovich, D. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0297 · Cited by 1,882
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0413-z · Cited by 1,349
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected
Marvel, D., & Gabrilovich, D. I. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80005 · Cited by 1,050
Bruchard, M., Mignot, G., Derangère, V., Chalmin, F., Chevriaux, A., Végran, F., Boireau, W., Simon, B., Ryffel, B., Connat, J. L., et al. (2013) · Nature Medicine · doi:10.1038/nm.2999 · Cited by 774
Steggerda, S. M., Bennett, M. K., Chen, J., Emberley, E., Huang, T., Janes, J. R., Li, W., MacKinnon, A. L., Makkouk, A., Marguier, G., et al. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0308-4 · Cited by 476
Metadata
- Authors
- Le, H. K., Graham, L., Cha, E., Morales, J. K., Manjili, M. H., & Bear, H. D.
- Venue
- International Immunopharmacology
- Publisher
- Elsevier BV
- Published
- 2009-07
- Volume
- 9
- Issue
- 7-8
- Pages
- 900-909
- ISSN
- 1567-5769 (ISSN-L)
- OpenAlex
- W2059492353
- Cited by
- 368
- References
- 45
- FWCI
- 7.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.